The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and significant returns is certain, the linked risks are also considerable. Many o